4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Combatting Bacterial Resistance in Europe (COMBACTE-NET)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2019,
... by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organis ...
Voir le projet
38
Participants partenaires
TERMINÉ
Incorporating real-life clinical data into drug development (GETREAL)
Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,
...it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA agencies and other healthcare decision m ...
Voir le projet
32
Participants partenaires
TERMINÉ
European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)
Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,
...onomous University of Barcelona, the Erasmus University Medical Center, the University of Utrecht, the University of Hert[ordshire, the University of Verona, the Karolinska Institute and the European Medicines Agency. It will deliver programmes in harmacovigilance and Pharmacoepidemiology for continuing education diploma, Master’s degree as well as PhD and a short course orientated towards risk co ...
Voir le projet
24
Participants partenaires
TERMINÉ
Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)
Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,
...rts and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Agency (EMEA), willdevelop and test methods of proactive monitoring of drug safety and benefit risk (B/R) assessment utilising a large range of EU data sources and expertise. in partnership ...
Voir le projet